January 25, 2015 | The Israeli biopharmaceutical company Kite Pharma announced that it has expanded on its agreement with Tel Aviv’s Sourasky Medical Center that will help it research and develop its CAR T technology. CAR T is a cellular therapy that is used as part of Kite Pharma’s cancer immunotherapy treatments. As part of the agreement, Kite Pharma will partner with Prof. Zelig Eshhar, an expert in CAR T research and the Chair of Immunology Research at Sourasky. Kite Pharma was founded in 2009 and is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system’s ability to recognize and eradicate tumors.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments